Business
Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum
MOUNTAIN VIEW, Calif., March 13, 2026--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company’s management team will participate in a virtual fireside chat at the Stifel 2026 Virtual CNS Forum on March 17, 2026 at 12:00pm ET.
About this update from Alto Neuroscience, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1659,"height":537,"url":"https://media.zenfs.com/en/business-wire.com/cd8205cd92533eb04d8e5a8a91ca3d18"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/EtPQ9YmzlpxYRYnDgxHwKg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMxMTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/cd8205cd92533eb04d8e5a8a91ca3d18","width":960,"height":311},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/m8V.kmSy8NBKjk.PSVZ1aw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NzY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/cd8205cd92533eb04d8e5a8a91ca3d18","width":1200,"height":388}},"lazy":false},{"type":"text","content":"MOUNTAIN VIEW, Calif., March 13, 2026--(BUSINESS WIRE)--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company’s management team will participate in a virtual fireside chat at the Stifel 2026 Virtual CNS Forum on March 17, 2026 at 12:00pm ET.","length":418,"tagName":"p"},{"type":"text","content":"The presentation will be accessible via a live webcast on the Events and Presentations page in the Investors section of Alto’s website and a replay will be available following the presentation.","length":193,"tagName":"p"},{"type":"text","content":"About Alto Neuroscience","length":23,"tagName":"p"},{"type":"text","content":"Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in depression, schizophrenia, and other mental health conditions. For more information, visit www.altoneuroscience.com or follow Alto on X.","length":635,"tagName":"p"},{"type":"text","content":"Availability of Information on Alto’s Website","length":45,"tagName":"p"},{"type":"text","content":"Alto routinely uses its investor r...